• Dorsomorphin: AMPK Logic for Translational Research

  2026-09-17

  Dorsomorphin, also known as Compound C, is more than an AMPK inhibitor. Its reversible ATP-competitive activity and parallel effects on BMP signaling make it a powerful—yet deliberately interpreted—tool for connecting metabolic control, autophagy, neural plasticity, differentiation, and translational disease models.

• PHF2 Links Neuroinflammation to Memory Loss in Alzheimer’s

  2026-09-17

  A 2025 Molecular Psychiatry study identifies the histone demethylase PHF2 as an epigenetic regulator of inflammatory gene expression in Alzheimer’s disease. By combining human, cellular, genomic, and 5xFAD mouse evidence, the researchers connect PHF2 knockdown with reduced glial activation, improved glutamatergic synaptic function, and better spatial memory.

• SB 431542: ALK5 Inhibitor Workflow Guide

  2026-09-16

  Learn how to use SB 431542 to test ALK5-dependent TGF-β responses in endothelial, tumor, and immune-cell models. This guide translates a PM2.5-induced EndMT study into practical controls, dosing logic, readouts, and troubleshooting steps.

• AZD3463: Translational Strategy for ALK-Driven Cancer

  2026-09-16

  A mechanism-first guide to positioning AZD3463 in ALK-driven cancer research, from pathway interrogation and combination design to biomarker strategy and preclinical translation.

• RepSox and the Next Frontier of iPSC Platelet Manufacturing

  2026-09-15

  RepSox offers a precise ALK5-centered approach for testing how TGF-β signaling shapes iPSC reprogramming, megakaryocyte maturation, and platelet manufacturing. This evidence-aware perspective connects mechanism with assay design, translational strategy, and the limits of extrapolating from pathway biology to scalable cell production.

• Anlotinib Hydrochloride in Angiogenesis Assays

  2026-09-15

  Anlotinib hydrochloride provides a practical way to interrogate VEGFR2, PDGFRβ, FGFR1, and downstream ERK signaling in endothelial and tumor-angiogenesis models. This guide translates published migration, tube-formation, ex vivo, and in vivo findings into an assay-ready workflow with optimization and troubleshooting advice.

• Thioredoxin Control of CHK1 Inhibitor Sensitivity

  2026-09-14

  A 2024 Nature Communications study identifies thioredoxin 1 as a determinant of checkpoint kinase 1 inhibitor response in non-small cell lung cancer. Its central mechanistic insight is that redox recycling of RRM1 sustains ribonucleotide reductase activity and deoxynucleotide availability, providing a rationale for combining CHK1 inhibition with thioredoxin reductase blockade.

• SU5416 (Semaxanib) Angiogenesis Workflows

  2026-09-14

  SU5416 (Semaxanib) combines selective VEGFR2 blockade with a useful AHR-related immune research angle. This practical guide shows how to connect endothelial assays, tumor vascularization studies, and HIF1α-focused metabolic experiments without overinterpreting pathway overlap.

• H 89 2HCl: Reading PKA Signals in Pain

  2026-09-13

  H 89 2HCl enables targeted interrogation of PKA-dependent phosphorylation without directly lowering cAMP. This article connects its pharmacology to trigeminal pain research while emphasizing off-target controls, assay design, and mechanistic interpretation.

• SP600125 in TLR-Driven Inflammation

  2026-09-12

  SP600125 is a JNK inhibitor for dissecting how TLR2/TLR4 signals become inflammatory cytokine outputs. This guide translates the CPSIT_0844 study into a rigorous assay strategy for kinase validation, cytokine expression modulation, and inflammation research.

• LY-411575: Gamma-Secretase Inhibitor Workflows

  2026-09-11

  LY-411575 enables controlled interrogation of amyloid beta processing and Notch-dependent signaling in cell, membrane, and disease-relevant models. This practical guide connects dose-response design, orthogonal readouts, and TNBC immune-microenvironment biology while highlighting selectivity limits and troubleshooting priorities.

• Rhodamine B Workflows for Nanomedicine Imaging

  2026-09-11

  Rhodamine B converts nanoparticle delivery, cell labeling, and tissue-distribution questions into measurable fluorescence readouts. This guide adapts the trypsin-responsive pancreatitis nanomedicine study into practical imaging workflows while separating validated findings from assay-starting recommendations.

• Batimastat (BB-94): Compartment-Aware MMP Assays

  2026-09-10

  Batimastat (BB-94) is a broad-spectrum hydroxamate MMP inhibitor for dissecting extracellular proteolysis. This guide develops a compartment-aware assay strategy linking MMP activity, BDNF processing, neuromuscular junction assembly, and tumor biology without overstating what the reference study directly demonstrated.

• Oteseconazole: From MIC Data to DDI Insight

  2026-09-10

  Oteseconazole (VT-1161) is a selective tetrazole CYP51 inhibitor with potent activity against Candida. This article presents a DDI-aware framework for interpreting susceptibility data, designing translational assays, and evaluating its relevance to recurrent vulvovaginal candidiasis research.

• UBA1, ATG5, and Autophagy in Cardiac Hypertrophy

  2026-09-09

  Lin and colleagues identify UBA1 as a regulator of pathological cardiac hypertrophy that acts by promoting ATG5 ubiquitination and suppressing autophagy. Their combination of pressure-overload modeling, viral gene perturbation, and mechanistic rescue experiments links ubiquitin-dependent ATG5 loss to cardiac remodeling, fibrosis, oxidative stress, and dysfunction.

8047 records 1/537 page Next 12345 下5页 Last page